Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 8;14(14):2333–2339. doi: 10.1080/15384101.2015.1044170

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 1. — Protective effects of fasting against side-effects of irinotecan in Apc-mutant mice. Side-effects were monitored from the start of the fasting regimen until 11 days after the first irinotecan injection (*). Graphs represent a total of 36 mice: 1. Ad libitum group (n = 9; males (m) n = 4, females (f) n = 5), 2. Fasted group (n = 9; m, n = 4, f, n = 5), 3. Ad libitum group treated with irinotecan (n = 10; m, n = 5, f, n = 5), and 4. Fasted group treated with irinotecan (n = 8; m, n = 4, f, n = 4). (A) Effects of fasting and irinotecan treatment on body weight. Fasted (F) mice lost weight during the fasting regimen, but gained weight during irinotecan treatment. In contrast, ad libitum (AL) fed animals lost weight during irinotecan administration. (B–E) Effects of fasting and irinotecan treatment on activity, coat, posture, and stool. ***Indicates significant difference (P < 0.001) between ad libitum fed animals treated with irinotecan compared to each of the other groups. (F) Effect of fasting and irinotecan treatment on bone marrow toxicity. Number of leukocytes on day 8 after the first irinotecan injection was significantly lower in ad libitum fed animals compared to fasted animals in the irinotecan treated groups. ***P < 0.001.